Breast Cancer
All4Cure: Triple Negative Breast Cancer
Genomic testing provides a “blue print” of tumor cells, identifying potential targets for therapy. The All4Cure study convenes experts across the country to discuss previously successful treatments for targets. Data is shared on an online technology platform which enables patients to better understand cancer and better inform treatment decisions by oncologists.
Study Objectives
All4Cure aims to accelerate learning about cancer by sharing medical information and research results from cancer patients with fellow cancer patients, oncologists, and scientists on the All4Cure website with the hope that together patients, clinicians and researchers can cure cancer faster.
Treatment Information
The core hypothesis tested by this study is that engaging researchers, clinicians and patients in an online knowledge sharing platform will enable patients to better understand cancer, better inform treatment decisions made by oncologists and accelerate cancer research. Leftover samples from patients with cancer (blood, bodily fluids and/or tissues collected for clinical purposes) will be obtained and sent for various types of analyses and results will be shared on the All4Cure website.
Patient Population
Females with triple negative breast cancer
Patients must be at least 18 years of age
Disease suitable for biopsy including bone disease or have tumor tissue available from a previous biopsy
Number of Patients: 5000
On-Site Study Visits
Screening period (typically 1 day) where consent is signed, blood drawn, enrollment procedures completed
Active study period: patients are seen by their oncologist for their standard of care appointments. No extra study visits are required
Long-term Follow-up
Patients may withdraw at any time. We plan to follow patients indefinitely or for as long as they agree to be in the study, depending on the availability of resources.
